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Abstract
Radiopharmaceuticals reflect physiologic and pathologic functions rather 
than anatomical abnormalities. In the clinical setting, it is often necessary 
to correlate these functional studies using anatomical imaging. The advent 
of single photon emission computed tomography (SPECT) and positron 
emission tomography (PET) provides tomographic images for direct cor-
relation to anatomic modalities such as X-ray, computed tomography (CT) 
and magnetic resonance imaging. Correlation of anatomic and functional 
information can aid in the decision-making process by enabling better 
localization and definition of organs and lesions and improving the preci-
sion of surgical biopsies. The advantages of combining SPECT with CT are 
primarily due to the anatomical referencing and the attenuation correc-
tion capabilities of CT. Depending on the system design, there are varying 
technical issues surrounding the different SPECT/CT devices. The princi-
ple of the integrated SPECT/CT instrumentation and the use of attenuation 
correction and anatomical referencing are discussed in this review. The 
specific disease processes where SPECT/CT has had a positive impact on 
diagnostic accuracy will be illustrated in this review. Although it is starting 
more slowly than PET/CT, SPECT/CT has many existing and potential areas 
of clinical application and has significantly added to the diagnostic power 
of nuclear medicine. Through literature review and case presentation, the 
authors illustrate the applications and uses of SPECT/CT as experienced at 
Tzu Chi General Hospital. The most common uses of SPECT/CT were for 
the diagnoses of infections focused with gallium-67 citrate, 99mTc-sulfur-
colloid sentinel lymph node mapping, thyroid cancer survey with 131I-sodium 
iodide, parathyroid scan with 99mTc-Sestamibi, abdominal diseases, and 
bone imaging with 99mTc-methylene diphosphonate. Through this review, 
the authors also highlight the current comprehensive clinical use of SPECT/
CT in our hospital. [Tzu Chi Med J 2008;20(4):253–269]
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1. Introduction
During the past 10 years, there has been growing uti-
lization of positron emission tomography (PET) due 
to health care insurance reimbursement for cancer 
staging and therapy response evaluation [1]. A great 
deal of the use of PET scans has also been stimulated 
by its co-registration with computed tomography (CT) 
acquired during the same patient visit. These PET/CT 
fusion studies produce functional and anatomic cor-
relative images that may add greater specificity and 
sensitivity than previously available from radionuclide 
studies alone [1].
The traditional nuclear medicine procedures with 
single-photon tracers still constitute the majority of 
clinical services. In recent years, single photon emis-
sion computed tomography (SPECT) and CT fusion has 
become commercially available. The concept of com-
bining SPECT studies with CT acquired during a single 
examination has stimulated a great deal of produc-
tive basic and clinical research [1]. Several companies 
are now offering these instruments, which include the 
GE Hawkeye system (GE Healthcare, Haifa, Israel), the 
Symbia system (Siemens Medical Solutions, Hoffman 
Estates, IL, USA), and the Precedence system (Philips 
Medical Systems, Milpitas, CA, USA). The development 
principle of various SPECT/CT devices and important 
considerations such as attenuation correction and co-
registration are discussed in the first section of this 
article.
Although the system started later than PET/CT, 
SPECT/CT has many existing and potential areas of 
clinical application and has significantly added to the 
diagnostic power of nuclear medicine. The specific 
disease processes where SPECT/CT has had positive 
impact on diagnostic accuracy are illustrated in this ar-
ticle. Examples include infection studies with gallium-67 
citrate (67Ga), bone imaging with 99mTc-methylene di-
phosphonate (99mTc-MDP), 99mTc-sulfur-colloid (99mTc-
S-colloid) sentinel lymph node mapping, thyroid cancer 
survey with 131I-sodium iodide (131I), and parathyroid 
scan with 99mTc-Sestamibi (99mTc-MIBI) (Table 1).
2. SPECT/CT principles and 
instrumentation
The advantages of combining SPECT with CT are nu-
merous and are primarily due to the anatomic refer-
encing and attenuation correction capabilities of CT. 
Technical developments over the past 20 years have 
led to the development of better software techniques 
for image fusion. While hardware image fusion tech-
niques have been in clinical use for many years, the 
first commercial SPECT/CT system was the GE Hawkeye 
system (GE Healthcare), which was developed in 
1999 [2].
There are varying technical issues surrounding the 
different SPECT/CT devices, ranging from cost, radia-
tion dosages, treatment planning, and sitting require-
ments to system-specific issues such as table sag and 
CT artifacts due to patient motion. As this technol-
ogy matures, we can expect to see a range of SPECT/
CT devices available on the market that range from 
low-dose 1–4 slice inexpensive CT upgrades of con-
ventional SPECT systems, to SPECT systems incorpo-
rating 64- or 128-slice CT scanners. The justification 
for such devices will be heavily dependent on clear 
demonstration of their value in clinical practice [3].
Much of the early work on the development of 
a combined SPECT/CT unit was performed at the 
University of California, San Francisco by Hasagawa 
et al [4] and Lang et al [5] in the early 1990s. Their 
initial work focused on the development of a system 
Table 1 — Clinical applications and abbreviations of radiopharmaceuticals for SPECT images mentioned in this review
Radiopharmaceuticals Abbreviation Clinical applications
Gallium-67 citrate 67Ga Inflammation and tumor scan
Technetium-99m methylene diphosphonate  99mTc-MDP Bone scan
Technetium-99m sulfur colloid  99mTc-S-colloid Sentinel lymph node
  Liver-spleen scan
Technetium-99m sestamibi 99mTc-MIBI Parathyroid scan
  Myocardial perfusion scan
Technetium-99m ethyl cysteinate dimer  99mTc-ECD  Cerebral perfusion scan
Technetium-99m TRODAT 99mTc-TRODAT Brain dopamine transporter scan
Technetium-99m dimercaptosuccinic acid 99mTc-DMSA Renal cortical scan
Technetium-99m labeled red blood cell 99mTc-RBC Gastrointestinal bleeding scan
Technetium-99m fanolesomab 99mTc-fanolesomab  Infectious scan
Technetium-99m ciprofloxacin 99mTc-ciprofloxacin Infectious scan
Iodine-131 sodium iodide  131I Thyroid scan
  Thyroid cancer work-up
Iodine-131 metaiodobenzylguanidine 131I-MIBG Adrenal medulla scan
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that could perform simultaneous CT and SPECT stud-
ies. Their work highlighted, for the first time, the poten-
tial benefits of a single device capable of performing 
anatomic and functional imaging. They demonstrated 
that such a system was capable of performing attenu-
ation correction and could permit accurate quantifi-
cation of radiotracer activity in a porcine myocardium 
[6]. This group was also the first to build a combined 
SPECT/CT system for clinical studies [7]. This system 
used a single-slice CT scanner and a single-head large 
field of view gamma camera and was the forerunner 
of today’s systems that combine a multidetector CT 
(MDCT) system and dual-detector SPECT system.
2.1. SPECT/CT devices in clinical service
2.1.1. Low current CT add-on conventional 
SPECT system
The first commercial SPECT/CT system was the GE 
Hawkeye system (GE Healthcare), which was developed 
in 1999 [2]. This system took advantage of the unique 
slip-ring gantry of the system to mount an X-ray tube 
emitting a fan-beam of radiation on detectors at the 
opposite sides of the slip-ring gantry. The mechani-
cal constraints placed by the heavy detectors limited 
the CT rotational speed. For a transaxial slice, each 
slice had an axial thickness of 10 mm. The X-ray system 
operated at 140 kVp with a tube current of 2.5 mA. 
Although this resulted in a significantly lower patient 
dose by a factor of 4 to 5, the quality of the CT images 
were inferior to that of state-of-the-art CT scanners [3].
The recently developed Hawkeye-4 (Fig. 1A) uses 
the same gantry as the original Hawkeye system and 
acquires four 5-mm thick slices with each rotation 
instead of one 10-mm slice. This design retains the 
very compact design of the Hawkeye system, deliv-
ers a low radiation dose to the patient and requires 
minimal room shielding [3]. The primary purpose of 
the Hawkeye system was not image fusion but rather 
the production of a high-quality attenuation map for 
use with the emission data. In this respect, the slow 
scan speed was advantageous in that breath holding 
was not possible and the CT images were blurred by 
respiratory and cardiac motion in a comparable man-
ner to the SPECT raw data. As of the end of March 
2008, six Hawkeye-4 systems have been installed in 
hospitals in Taiwan.
2.1.2. Integrated SPECT/CT systems with 
high-quality CT
Two vendors have opted for the development of SPECT/
CT systems that are more comparable to their PET/CT 
counterparts, with the goal of providing high-quality CT 
images fused to the SPECT image data. The Precedence 
system from Philips Medical Systems couples a con-
ventional 6-slice or 16-slice CT scanner to their dual-
detector Skylight system. So far, no Precedence system 
has been installed in Taiwan.
The Symbia system (Siemens Medical Solutions) 
incorporates 1-, 2- or 6-slice CT scanners with their 
dual-detector E-Cam system (Fig. 1B) [3]. With both 
systems, CT slice thickness is variable and can be 
adjusted from 0.6 mm up to 10 mm. The scan speed 
A B
Fig. 1 — (A) The GE Hawkeye 4® system installed in Tzu Chi General Hospital. The X-ray tube housing is seen on the left 
side of the gantry with the array of detectors on the right side. (B) The Siemens Symbia® system installed in National 
Taiwan University Hospital. This is an integrated gantry that contains a multidetector row CT system and dual-detector 
E-Cam system (courtesy of Dr Kai-Yuan Tzen at the National Taiwan University Hospital, Taipei, Taiwan).
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for a 40-cm axial field of view is less than 30 seconds. 
In comparison, the CT scan time on the GE Hawkeye-4 
system is 5 minutes for a 40-cm field of view [3]. 
However, because of the addition of a separate CT 
gantry, both the Symbia and Precedence systems are 
considerably larger than the conventional SPECT sys-
tems and have very different sitting and shielding re-
quirements compared with the GE Hawkeye system. 
As of the end of March 2008, three Symbia systems 
have been installed in hospitals in Taiwan. Whether 
the CT component in the combined imaging approach 
should be a conventional MDCT scanner or the more 
compact, low current CT add-on used in the GE Hawkeye 
system is currently still a matter of debate.
3. Advantages of SPECT/CT: attenuation 
correction and anatomic referencing
The advantages of combining SPECT with CT are pri-
marily due to the attenuation correction and anatomic 
referencing capabilities of CT (see below). Due to these 
two purposes, ensuring that the CT and SPECT im-
ages are correctly co-registered in three dimensions 
is important.
3.1. Attenuation correction
To correct SPECT images for attenuation, the spatial 
distribution of attenuation coefficients within the pa-
tient must be known. This attenuation map is then 
incorporated into a statistically based, iterative recon-
struction algorithm such as ordered subset expectation 
maximization (OSEM) [8,9]. In the current SPECT/CT 
system, the spatial distribution of attenuation coeffi-
cients is measured using a CT scanner. With any type 
of CT system, the image noise in attenuation maps is 
very low, and the in-plane resolution is high compared 
with maps generated from radionuclide-based trans-
mission systems. Although CT systems generate a 
higher resolution map, improvement in the resolution 
is not necessarily a factor in the accuracy of the atten-
uation compensation because we are primarily con-
cerned with obtaining an accurate estimation of the 
attenuation path length for each pixel in the SPECT 
transaxial data [3].
For the use of attenuation correction, the most 
frequent clinical studies include cerebral perfusion 
imaging with 99mTc-ethyl cysteinate dimer (99mTc-ECD) 
and brain dopamine transporter imaging with 99mTc-
TRODAT. Special attention has to be paid with regard 
to the possible mis-registration between the CT and 
SPECT images causing errors on attenuation correc-
tion. However, we would like to focus this review on 
the clinical applications and usefulness of integrated 
SPECT/CT imaging. We leave the discussion of the 
physics and instrumental aspects of the SPECT/CT 
scan for attenuation correction and technical issues 
causing possible pitfalls to future papers from our 
group.
3.2. Anatomic referencing
For co-registration of anatomic and functional infor-
mation, the accurate co-registration of the SPECT and 
CT data are just as important as with the attenuation 
correction. Many of the pitfalls such as patient motion 
as well as respiratory and cardiac motion all apply 
equally to image fusion. Usually, a calibration proce-
dure is needed to ensure that both the CT and SPECT 
images are correctly co-registered in three dimensions. 
For the GE Hawkeye-4 system, a series of six syringes 
containing an appropriate radionuclide are inserted 
into a foam calibration phantom so that they are orien-
tated in three orthogonal planes (Fig. 2). After SPECT/
CT acquisition, the software is used to automatically 
determine the location of the syringes and either com-
putes the necessary calibration factors to ensure pre-
cise alignment of the CT and SPECT images or, on 
a routine basis, confirms the validity of the existing 
calibration factors. This type of calibration procedure 
is essential if the clinician is to have confidence in the 
ability of the technology to permit accurate localiza-
tion of radiotracer uptake in the body [3].
Fig. 2 — To ensure that the CT and SPECT images are 
correctly co-registered in three dimensions, a series of 6 
syringes (3 of which can be seen in the photograph, the 
other 3 are on the reverse side of the phantom) contain-
ing an appropriate radionuclide are inserted into a foam 
calibration phantom so that they are orientated in three 
orthogonal planes. When imaged on both the SPECT and 
CT systems, they permit accurate alignment of the CT 
and SPECT data. The calibration system is used for the 
GE Hawkeye 4 system.
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For the use of anatomic referencing, the most fre-
quent clinical studies include infection studies with 
67Ga-citrate, thyroid cancer survey with 131I, and para-
thyroid scan with 99mTc-MIBI, 99mTc-S-colloid sentinel 
lymph node mapping, and bone imaging with 99mTc-
MDP. In the text, the authors give some examples of 
the routine clinical applications of SPECT/CT at the 
Tzu Chi General Hospital, Taipei Branch.
4. Clinical usefulness of SPECT/CT 
fusion imaging
4.1. Infection and inflammation
Two of the well-known radiopharmaceuticals used 
for the detection and localization of infection/
inflammation are 67Ga-citrate and radiolabeled white 
blood cells (WBCs). Newer agents such as radiola-
beled monoclonal antibodies, most commonly 99mTc-
fanolesomab [10] and 99mTc-ciprofloxacin [11,12], and 
18F-fluorodeoxyglucose (FDG) [13,14] have the poten-
tial for faster and more specific diagnoses. These ra-
diopharmaceuticals reflect physiologic and pathologic 
functions rather than anatomic abnormalities. In the 
clinical setting, it is often necessary to correlate these 
functional studies with anatomic imaging. 67Ga-citrate 
is a readily available radiopharmaceutical. It is easy to 
handle, unlike radiolabeled WBCs, requiring no blood 
sampling, labeling, and re-injection of blood products. 
67Ga is an iron analog [15]; it binds to iron-binding 
proteins of inflammatory cells, bacterial siderophores, 
or other mucopolysaccharide proteins [16].
For disseminated infectious lesions, the planar 
whole body 67Ga scan is useful for detecting multiple 
lesions in a single examination [17]. For some specific 
anatomic structures, 67Ga activity can be used to 
identify the specific pattern of uptake such as psoas 
abscess (Fig. 3) [18] or aortic arch septic aneurysm 
(Fig. 4) [19]. However, most of the 67Ga uptake lesions 




Fig. 3 — (A) Planar 67Ga scan revealed a band-shaped focal uptake in the paraspinal region, the direction of the lesion 
corresponding to the psoas muscle. (B) Magnetic resonance imaging revealed left psoas muscle abscess. (C) Serial 
coronal sections of 67Ga SPECT over the abdominal region confirmed the diagnosis of left psoas muscle abscess.
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The advent of SPECT provides tomographic images 
for direct correlation to CT and magnetic resonance 
imaging (MRI) anatomic modalities. Integrated SPECT 
and CT increase the specificity of the physiologic mo-
dality and increase the sensitivity of the anatomic 
modality. In one of the earlier studies, Swayne per-
formed a prospective evaluation of software SPECT 
and CT fusion in 10 patients with suggested inflam-
matory disease [23]. Correct localization was found 
in all 10 patients, suggesting that the method is an 
accurate one of functional and anatomic correlation. 
Several subsequent investigations have shown that 
SPECT/CT fusion is beneficial to the interpretation in 
a majority of cases and increases sensitivity and spe-
cificity [24]. With integrated SPECT/CT images, 67Ga 
uptake lesion involved in the tissues and organs can 
be clearly identified using CT images (Figs. 5 and 6).
4.2. Endocrine tumors
The introduction of SPECT/CT into the field of endo-
crinology led to a major breakthrough in the diag-
nosis and management of patients with endocrine 
tumors. The scintigraphic functional techniques for the 
diagnosis of endocrine tumors are mainly associated 
with the unique uptake and transport mechanisms 
and with the presence of high densities of membrane 
receptors on some of these tumors, which reflect the 
pathophysiologic status of the disease process. However, 
lack of structural delineation and relatively low con-
trast may mix up the localization of the abnormal func-
tional findings with the physiologic biodistribution of 
the radiotracers. In the past, simultaneous dual-tracer 
image such as combined 131I-metaiodobenzylguanidine 
(131I-MIBG) and 99mTc-MDP bone scan or 99mTc-
dimercaptosuccinic acid (99mTc-DMSA) renal cortical 
scan for localization of pheochromocytoma or neuro-
blastoma [25,26], failed to provide accurate anatomic 
localization of neuroendocrine tumors.
Anatomic high-resolution and functional imaging 
data acting as complementary methods led to various 
combination techniques of these modalities. SPECT/
CT enables the sequential acquisition of the two mo-
dalities, with subsequent merging of data into a com-
posite image display. We present two examples of the 
contribution of integrated SPECT/CT technology for 
image analysis and management of patients with well 




Fig. 4 — (A) Planar 67Ga scan revealed an arch-like focal uptake in the upper mediastinal region, the shape of the lesion 
corresponding to the aortic arch in the upper chest region. (B) Chest CT showed mediastinal abscess with mycotic 
aneurysm of the aortic arch and subclavian artery. (C) Serial coronal sections of chest 67Ga SPECT revealed that the 
arch-like 67Ga-avid lesion corresponded to the aortic arch.
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4.2.1. 131I SPECT/CT for WDTC
Whole body 131I scanning can be used to detect resid-
ual or recurrent WDTC and metastatic tumor before 
visualization on anatomic imaging modalities. 131I-
avid malignant foci can then be removed surgically 
or be treated with high doses of 131I. Because of a 
lack of anatomic landmarks, abnormalities detected 
on 131I planar whole body scan and SPECT are diffi-
cult to interpret. Normal active radioiodine transport 
in the salivary glands, nasopharynx, gastric mucosa, 
and breast tissue may cause missed diagnosis of WDTC 
lesions. Diagnostic pitfalls leading to the need for ad-
ditional images or diagnostic procedures were found 
in 59% of a total of 500 whole-body 131I scans from 
300 consecutive patients, mainly as the result of con-
tamination, intestinal retention, hot nose, unexpected 
breast activity [27], as well as kidney and isolated peri-
pheral metastasis [28].
The incremental value of SPECT/CT was docu-
mented in a preliminary report of 54 patients who 
underwent 67 SPECT/CT studies along with 565 131I 
whole body scans of 298 patients with WDTC during 
a 40-month period [29]. SPECT/CT was performed in 
these patients when an extrathyroidal 131I-avid site 
could not be attributed to physiologic uptake or to a 
well-defined metastasis (Fig. 7). SPECT/CT contrib-
uted to image interpretation of 54 among the 80 ill-
defined 131I-avid foci (68%) in 38 patients (70%), 
mainly in cervical nodes, pelvic soft tissue and bone. 
SPECT/CT affected the management of 22 patients 
(41%). These management changes included: (1) diag-
nosis of bone metastasis led to radiation therapy in 
three patients; (2) identification of resectable tumor 
mass for surgery in three patients; (3) and avoidance 
of unnecessary 131I treatment after the recognition of 
physiologic 131I activity in 16 patients [29].
Fig. 5 — A 76-year-old female with urinary tract infection and persistent fever after treatment was referred for 67Ga 
whole body survey. Abdominal CT showed splenomegaly with multifocal hypodense areas in the splenic parenchyma 
and prominent of uterus cavity, splenic infarction was suspected. (A) Whole body 67Ga scan revealed multiple areas of 
increased 67Ga accumulation involving the right cardiac region, spleen, bilateral kidneys, and lower pelvis around the 
uterus region. Disseminated infectious foci were diagnosed. (B) 67Ga SPECT/CT over the lower chest to upper abdominal 
region demonstrated abnormal splenic 67Ga accumulation with segmental cold defects (asterisk) suggestive of diffuse 
splenic infection with focal infarctions. The right cardiac lesion also became more prominent in the SPECT/CT images 
(red arrow).
A B
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In another study of 25 patients with inconclusive 
whole body findings after ablative radioiodine ther-
apy, SPECT/CT improved the anatomic assignment in 
17 of 39 sites (44%) with changes in management in 
six of 24 (25%) patients [30]. When we compared 131I 
SPECT/CT to planar imaging in 71 patients, incremen-
tal value of SPECT/CT was documented in 41 of the 
71 patients (57%). Major changes in management were 
observed when SPECT/CT provided better localiza-
tion of 131I uptake to lymph node metastases versus 
remnant thyroid tissue, to the lung versus mediastinal 
metastases, and to the skeleton [31].
With an anterior upper mediastinal mass, the dif-
ferential diagnoses included thymoma, teratoma, 
thyroid tumor or goiter, and lymphoma. The authors 
used low-dose 131I SPECT/CT to define a huge upper 
mediastinal tumor as an intrathoracic goiter. The 131I 
SPECT/CT images correlated well with diagnostic CT 
and confirmed the diagnosis of intrathoracic goiter 
(Fig. 8).
4.2.2. 99mTc-MIBI SPECT/CT for localizing 
parathyroid adenoma
99mTc-MIBI is a lipophilic cationic complex used pri-
marily for the detection of myocardial perfusion 
abnormalities. 99mTc-MIBI also accumulates nonspe-
cifically in various tumors, such as breast tumors and 
parathyroid adenomas. Although the exact mechanism 
is not fully understood, mitochondria have been impli-
cated in its uptake by parathyroid cells [32]. Also, the 
sizes and cellularity of the abnormal glands correlated 
with the uptake of 99mTc-MIBI [33].
Parathyroid adenomas account for 85% of hyper-
parathyroidism cases. Preoperative localization of 
parathyroid adenomas has gradually become impor-
tant since the widespread use of minimally invasive 
surgical procedures in patients with primary hyper-
parathyroidism. Minimally invasive procedures have 
been associated with decreased risk of hypoparathy-
roidism and of recurrent laryngeal nerve injury, as 
well as shortening of surgery time and hospitalization. 
A B
C D
Fig. 6 — A 73-year-old diabetic man with left facial palsy was diagnosed with necrotizing otitis media which suggested 
skull base and temporal bone involvement. Whole body 67Ga scan was performed to determine the territory of infection 
involvement. (A, B, C) Serial transaxial sections of 67Ga SPECT/CT fusion images and (D) left lateral projection image 
over the skull revealed that the 67Ga-avid lesion involved the arch of the left zygomatic bone to the left external and 
middle ear, left masticator space, and mastoid region, compatible with otitis media with adjacent skull base bone and 
soft tissue involvement.
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The limited surgical procedures include minimally in-
vasive parathyroidectomy, endoscopic surgery [34], 
and video-assisted thoracic surgery for resection of 
ectopic mediastinal parathyroid glands [35].
In the late 1990s, planar 99mTc-MIBI scintigraphy 
was confirmed to play a major role in the preopera-
tive localization of parathyroid adenomas [36,37]. It 
is believed that the combined approach of planar 
Fig. 8 — A 75-year-old female was diagnosed to have a large upper mediastinal mass on chest CT. 131I thyroid scan was 
performed to rule out intrathoracic goiter. (A) Low-dose 131I revealed normal thyroid glands with a huge heterogeneous 
131I accumulation lesion in the right upper chest region. (B) Coronal view of the 131I SPECT/CT fusion image revealed 
that the upper chest 131I accumulation corresponded to the upper mediastinal mass found on diagnostic chest CT.
A B
A B
Fig. 7 — (A) Posterior view of a low-dose 131I whole-body scan of a 35-year-old female WDTC patient shows a focal area 
of abnormal 131I accumulation in the right mid portion of the body (arrow). (B) Transaxial SPECT/CT imaging over the 
lower chest to upper abdominal region revealed that the 131I-avid lesion was localized in the right lobe of the liver on 
the fusion image (arrow). The results of SPECT/CT indicated the need for large-dose 131I therapy.
262 TZU CHI MED J  December 2008  Vol 20  No 4
99mTc-MIBI and ultrasonography (US) is considered the 
diagnostic strategy of choice for noninvasive detection 
of parathyroid adenomas located in the neck, with a 
sensitivity of 83% for US and 85% for subtraction 
MIBI, and increasing to 94% when using the combined 
imaging approach [38].
In addition to planar 99mTc-MIBI scintigraphy, 99mTc-
MIBI-SPECT reached 96% sensitivity, superior to that 
of planar imaging (79%) [39]. However, even 99mTc-
MIBI SPECT may not provide detailed anatomic infor-
mation; therefore, co-registration of 99mTc-MIBI and CT 
has been suggested. In a study of 48 patients with 
primary hyperparathyroidism, SPECT/CT data were 
compared with those of SPECT only. SPECT-only im-
aging identified 89% of the surgically confirmed dis-
eased parathyroid glands, and SPECT/CT improved 
localization of parathyroid adenomas in four patients 
(8%). SPECT/CT was particularly helpful in locating 
two ectopic parathyroid adenomas (Fig. 9) [40]. The 
usefulness of SPECT/CT in ectopic parathyroid ade-
nomas was reported in a study of 36 patients with pri-
mary hyperparathyroidism [41]. 99mTc-MIBI SPECT/CT 
facilitated surgical exploration in all 10 ectopic par-
athyroid adenomas, but only in four of 23 cervical 
adenomas. In these 10 patients with lower neck/
mediastinal parathyroid adenomas, SPECT/CT identi-
fied their proximities to the trachea, esophagus, thy-
mus, spine, or sternum and optimized the surgical 
procedure in these patients. In addition, SPECT/CT 
facilitated the surgical resection of four adenomas in a 
subgroup of six patients scheduled for re-exploration 
after failed initial surgery. SPECT/CT provides better 
definition of organs and tumors that take up the ra-
diotracers and of their precise relationship with adja-
cent structures, defines the functional significance 
of CT lesions and improves the specificity of SPECT 
by excluding diseases at sites of physiologic uptake or 
excretion.
4.3. Abdominal disease
In SPECT studies of abdominal diseases, SPECT/CT 




Fig. 9 — 99mTc-MIBI dual-phase parathyroid scan (A) at 10 minutes and (B) 2 hours after injection of the radioagent 
revealed a focal area of abnormal radioactivity uptake and retention inferior to the left lobe of the thyroid. (C) 99mTc-
MIBI SPECT/CT images (displayed from left to right in coronal, sagittal, and transaxial sections, respectively) clearly 
demonstrated the anatomic location of the parathyroid adenoma. The multipanel display format provides surgeons 
with more informative ectopic parathyroid adenoma location for better preoperative planning.
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hemangiomas located near vascular structures, in 
precisely detecting and locating active splenic tissue 
caused by splenosis in splenectomy patients, in pro-
viding important information for therapy optimization 
in patients undergoing hepatic arterial perfusion scin-
tigraphy, in accurately identifying the involved bowel 
segments in patients with inflammatory bowel diseases, 
and in correctly locating the bleeding sites in patients 
with gastrointestinal bleeding [42].
4.3.1. Hepatic hemangioma
Hemangioma is the most common benign tumor of 
the liver. According to an autopsy series, its preva-
lence ranges from 3% to 20% [43]. 99mTc-labeled red 
blood cell (99mTc-RBC) scintigraphy has proven to be 
an accurate and cost-effective noninvasive method 
to detect hepatic hemangiomas. It is able to improve 
the specificity of other imaging studies with a posi-
tive predictive value approaching 100% [44]. Because 
of its high specificity for the noninvasive diagnosis of 
hepatic hemangiomas, 99mTc-RBC scintigraphy can 
spare the patient an invasive angiogram or biopsy of 
a vascular mass. However, even on SPECT imaging, 
the sensitivity of this technique is limited to lesions 
smaller than 1 cm and those located in unfavorable 
topographic sites [45].
With software SPECT and CT/MRI fusion images of 
20 patients with 35 known hemangiomas, Birnbaum 
et al demonstrated the ease of identification of five of 
seven hemangiomas close to major intrahepatic blood 
vessels [46]. The major clinical advantages of image 
fusion were the diagnostic confirmation of small hem-
angiomas and the correct characterization of hot-spots 
detected on SPECT studies adjacent to regions of vas-
cular activity. However, the software fusion image proc-
ess is time-consuming for the processing of accurate 
landmark positioning.
In 2004, Schillaci et al performed a study to verify 
whether new SPECT/CT hardware fusion images were 
able to improve 99mTc-RBC in patients suspected to 
have liver hemangioma [47]. Twelve patients with sus-
pected hepatic hemangiomas were studied. A total 
of 24 lesions were identified on SPECT, including 21 
hemangiomas ranging from 0.6 cm to 4.2 cm in size; 
three hemangiomas (0.6 cm, 0.9 cm and 1 cm in size) 
were not identified on SPECT. In four (33.3%) of the 
12 patients, the combination of using SPECT/CT added 
significant information compared with using SPECT 
alone. Moreover, SPECT/CT improved the accuracy 
of 99mTc-RBC scintigraphy in correctly classifying the 
hepatic lesions evaluated as hemangiomas or non-
hemangiomas from 70.8% (17/24) to 87.5% (21/24).
In another study, Zheng et al demonstrated that 
SPECT/CT was used to correctly diagnose eight hem-
angiomas in less than ideal anatomic locations, includ-
ing four close to the inferior cava, three close to the 
abdominal aorta, and one close to the heart. These 
lesions were clearly difficult to be correctly charac-
terized using only SPECT [48].
4.3.2. Splenosis or accessory spleen
Splenosis is the autotransplantation of individual 
fragments of splenic tissue left behind after either 
operative or traumatic removal of the spleen [42]. 
Experimental evidence has suggested that the pres-
ence of an intact spleen suppresses the growth and 
development of splenic implants. However, the exis-
tence of splenosis or accessory spleens may cause 
recurrence in patients who undergo splenectomy for 
hematologic diseases, i.e., idiopathic thrombocyto-
penic purpura or hemolytic anemia; thus, finding the 
correct location of active splenic tissue is important 
for subsequent surgical treatment [49].
Splenic scintigraphy with 99mTc-labeled radiocolloids 
or heat-damaged RBC is the most sensitive method 
for detecting active splenic tissue [50]. Nevertheless, 
the precise locations of the sites of splenosis or acces-
sory spleen may be very difficult to determine because 
of the lack of anatomic landmarks. This drawback may 
be overcome by integrated SPECT/CT imaging acqui-
sition. Horger et al studied seven patients with history 
of either splenic trauma or splenectomy and hema-
tologic disorders [51]. They demonstrated that SPECT/
CT improved diagnostic accuracy when it allowed for 
correct classification of indeterminate masses, or when 
previously unknown splenic implants were detected. 
SPECT/CT image fusion is important to establish the 
correct diagnosis, to increase observer confidence, 
and to plan surgical treatment.
In another study conducted by Valdes Olmos et al, 
they demonstrated that SPECT/CT was very useful 
for the diagnosis of ectopic splenic tissue simulating 
abdominal tumors in cancer patients [52].
4.3.3. Gastrointestinal bleeding
99mTc-RBC has been demonstrated to be clinically 
useful in the evaluation of patients with acute gas-
trointestinal (GI) bleeding [53]. With regard to the 
usefulness of SPECT/CT in the detection of GI bleed-
ing, Yama et al reported a case of intestinal bleeding 
in which fused images from 99mTc-RBC SPECT and 
from CT revealed small intestinal bleeding with spe-
cific anatomic features for a more precise definition 
of the location of the GI bleeding source [54]. Inte-
grated SPECT/CT imaging was able to furnish a high 
degree of specific anatomic information to scintigra-
phic data when conventional scans are positive for 
bleeding (Fig. 10). CT imaging identified structures 
and increased the specificity of 99mTc-RBC in the di-
agnosis of acute GI bleeding. Moreover, integrated 
SPECT/CT was useful for allowing better localization 
of Meckel’s diverticulum using 99mTc-pertechnetate 
imaging to detect ectopic gastric mucosa as a source 
of lower GI bleeding [42].
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4.4. Sentinel lymph node mapping in 
breast cancer
The sentinel lymph node (SLN) is defined as the first 
node in the lymphatic drainage of the primary tumor. 
Tumor cells initially spread through the lymphatic 
pathway to one or more SLNs. Currently, in patients 
with breast cancer and malignant melanomas, SLN 
detection and biopsy have already been implemented 
into clinical practice [55,56]. The precise anatomic 
location of SLNs is important for minimally invasive 
surgery and to avoid incomplete removal of the SLNs. 
All SLNs should be resected to achieve complete nodal 
staging. Minimally invasive SLN biopsies have suc-
cessfully replaced lymphadenectomy for nodal stag-
ing [57,58]. Therefore, precise anatomic localization 
of SLNs preoperatively is very important for successful 
surgical outcomes.
Conventional planar imaging using dynamic data 
acquisition (Fig. 11) is initially used to preoperatively 
identify the anatomic localization of the detected nodes. 
With the lack of anatomic outlines and body back-
grounds, the certainty of the location of the nodes is 
still unsatisfactory. Even with the use of an intraopera-
tive handheld gamma probe detector, a noninvasive 
technique that allows for better preoperative local-
ization of SLNs and improvement in the detection rate 
is still needed.
With the use of SPECT/CT, combined metabolic 
and anatomic imaging in one single examination has 
been successfully used in SLN mapping [59,60]. The 
results of SPECT/CT imaging can categorize the SLNs 
according to the American Joint Committee on Cancer 
by using the pectoralis minor muscle border between 
Level I/II and Level II/III. Therefore, even small hot 
spots with no body background can be precisely lo-
cated. Husarik et al compared planar images, SPECT 
alone, and integrated SPECT/CT in SLN mapping in 
patients with breast cancer [59,60]. As compared with 
planar images, SPECT/CT showed more accurate in-
formation in 34 patients (82%). In 29 patients (70%), 
the exact anatomic location was equivocal on planar 
images, whereas SPECT/CT showed the exact anat-
omic information needed to assign SLN levels. In 
six patients (14%), SLNs close to the injection site 
were detected with SPECT/CT; however, those were 
not visible on planar images due to scatter radiation. 
As compared with SPECT alone, SPECT/CT showed 
more accurate information in 26 patients (63%). In 
these 26 patients (63%), the exact anatomic loca-
tions were impossible to visualize on SPECT images 
alone. SLNs close to injection sites were not detected 
using SPECT alone in three patients (17%) but could 
be clearly delineated on SPECT/CT due to the anat-
omic correlation in the form of lymph nodes. Husarik 
et al concluded that localization and identification of 
SLNs was more accurate using integrated SPECT/CT 
imaging in comparison with planar images and SPECT 
images alone, respectively.
Lerman and coworkers compared planar images 
to SPECT/CT in SLN mapping of breast cancer in 157 





Fig. 10 — 99mTc-RBC abdominal scan at (A) 2 hours and (B) 6 hours after the injection of a radioagent revealed pro-
gressive accumulation of radiotracer in the upper right quadrant of the abdomen, in the lower margin of the right lobe 
of the liver. (C) Coronal and (D) transaxial 99mTc-RBC SPECT/CT fusion images 6 hours after injection of a radioagent 
revealed abnormal radioactivity accumulation in the gallbladder (arrows).
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identified using lymphoscintigraphy on SPECT/CT due 
to the obscuring by scattered radiation from the injec-
tion site, and two SLNs were misinterpreted as one on 
planar images. In addition, unexpected sites of drain-
age were found in 33 patients.
From the literature review above, integrated SPECT/
CT was clearly superior to SPECT alone or planar 
images, especially with regard to exact anatomic lo-
calization of SLNs. The high anatomic accuracy of 
integrated SPECT/CT facilitates the detection of SLN 
during minimally invasive surgery. SPECT/CT images 
might replace external marking of the SLN before sur-
gery because of the high content of information of 
SPECT/CT images. With the newly developed imaging 
segmentation programs, SPECT/CT images can even 
co-register the SLN with the bone frame extracted from 
the CT images of SPECT/CT (Fig. 11) [62–64].
4.5. Bone tumor and malignant 
metastases survey
Whole body bone scans have been used clinically for 
more than 30 years and they are known as one of 
the most sensitive noninvasive methods for detecting 
focal bone pathology. In general, whole-body scans 
are used for bone scintigraphy, which permit the as-
sessment of the overall distribution of the radiophar-
maceutical. Both anterior and posterior studies are 
reviewed in parallel, thus, comparing any alterations, 
and noting eventual asymmetries on both sides of 
the midline. Additional spot views are obtained when 
specific clinical problems that need to be further clar-
ified are detected on whole-body imaging. Under cer-
tain conditions, such as local symptoms suggestive of 
metastases, additional SPECT scans of the body area 
in question should be considered to increase diag-
nostic sensitivity. Accurate differentiation between 
benign and malignant lesions is of paramount impor-
tance, which indicates short or limited survival and the 
need for intensified treatment of malignant lesions 
(Fig. 12) [65].
In patients with high risk of bone metastases, 
additional anatomic information is often necessary. 
Particularly, bone lesions located in the spine and 
thoracic cage cannot be sufficiently assessed using 
conventional radiographic examinations and instead 




Fig. 11 — A 50-year-old woman with left breast cancer was scheduled to undergo SLN mapping before her surgery. 
(A) Summation of dynamic lymphoscintigraphy after injection of 99mTc-S-colloid subdermally above the breast tumor 
clearly shows SLN in the left axillary region. (B) Summation of dynamic lymphoscintigraphy with cobalt-57 (57Co) radio-
active flood source was used to outline the body shape for better localization of the SLN. (C) Three different section 
displays of SPECT/CT images through the SLN revealed better relative anatomic localization of the SLN (asterisk) to the 
pectoralis muscle on the CT images.
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imaging has proven to be extremely useful in identi-
fying benign skeletal abnormalities, such as osteo-
chondrosis, spondylopathy, or degenerative spondyl 
arthrosis, as the reason for abnormal tracer uptake. 
A benefit of SPECT/CT is to help define bone lesions 
to guide subsequent biopsy [65,66].
There have many unexpected findings in patients 
with cancer who are undergoing bone scintigraphy 
for staging. Extraosseous uptake associated with cal-
cification might be found in some instances that 
cannot be correctly diagnosed without correspond-
ing anatomic images. Extraosseous uptake has been 
described in amyloidosis, rhabdomyolysis [67], high 
voltage electrical burn [68], infarction of heart, spleen 
(Fig. 13), intestine [69], and soft tissue tumor [70,71]. 
To differentiate this great variety of possible causes, 
morpholo gic information obtained by SPECT/CT is 
needed [65].
5. Conclusions
The concept of combining SPECT studies with CT 




Fig. 12 — A 54-year-old woman with facial bone and chest wall deformities was referred for 99mTc-MDP bone scan. 
(A) Anterior view of the whole-body bone scan revealed multiple bone lesions involving the nasal bone of the skull, 
left hemifacial bones, left rib cage, and left hemipelvic bones. The bone scan findings were suggestive of polyostotic 
fibrous dysplasia. (B, C, D) 99mTc-MDP bone SPECT/CT fusion images clearly demonstrated the territory of these bone 
lesions which still underwent active remodeling. SPECT/CT is especially useful in the three-dimensional display of bone 
involvement in craniofacial bones. Bone biopsy over the facial bone confirmed the diagnosis of fibrous dysplasia.
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a great deal of productive basic and clinical research 
which has resulted in successful clinical applications 
in a variety of diseases. In this review article, the au-
thors focused on specific disease processes where 
SPECT/CT has had a positive impact on diagnostic ac-
curacy and is currently being used in Tzu Chi General 
Hospital, Taipei Branch.
Hopefully, the specific role of SPECT/CT will con-
tinue to emerge as utilization of this approach in-
creases. Close and cooperative relationships between 
clinical physician and nuclear medicine physician are 
essential to the growth of SPECT/CT use in the coming 
decade.
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